Total Payments
$29,172
2024 Payments
$4,991
Companies
99
Transactions
1,586
Medicare Patients
6,062
Medicare Billing
$7.1M
Payment Breakdown by Category
Food & Beverage$27,846 (95.5%)
Other$550.00 (1.9%)
Consulting$400.00 (1.4%)
Education$376.41 (1.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $27,846 | 1,565 | 95.5% |
| Consulting Fee | $400.00 | 3 | 1.4% |
| Education | $376.41 | 15 | 1.3% |
| Honoraria | $350.00 | 2 | 1.2% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $200.00 | 1 | 0.7% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $2,285 | 126 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $2,078 | 119 | $0 (2024) |
| Merck Sharp & Dohme LLC | $1,398 | 69 | $0 (2024) |
| Genentech USA, Inc. | $1,269 | 89 | $0 (2024) |
| Celgene Corporation | $1,154 | 55 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $1,139 | 72 | $0 (2024) |
| PFIZER INC. | $1,125 | 81 | $0 (2024) |
| Lilly USA, LLC | $1,115 | 98 | $0 (2024) |
| Janssen Biotech, Inc. | $1,050 | 61 | $0 (2024) |
| Pharmacyclics LLC, An AbbVie Company | $986.87 | 47 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $4,991 | 235 | AstraZeneca Pharmaceuticals LP ($473.89) |
| 2023 | $4,099 | 206 | AstraZeneca Pharmaceuticals LP ($477.57) |
| 2022 | $2,740 | 133 | Janssen Pharmaceuticals, Inc ($242.35) |
| 2021 | $2,118 | 108 | Pharmacyclics LLC, An AbbVie Company ($204.51) |
| 2020 | $2,696 | 132 | Athenex Pharmaceutical Division, LLC ($350.00) |
| 2019 | $4,752 | 269 | E.R. Squibb & Sons, L.L.C. ($485.90) |
| 2018 | $3,701 | 252 | Lilly USA, LLC ($368.42) |
| 2017 | $4,075 | 251 | Genentech USA, Inc. ($486.04) |
All Payment Transactions
1,586 individual payment records from CMS Open Payments — Page 1 of 64
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $24.26 | General |
| Category: ONCOLOGY | ||||||
| 12/18/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $16.98 | General |
| Category: Rare Disease | ||||||
| 12/16/2024 | ABBVIE INC. | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $33.55 | General |
| Category: ONCOLOGY | ||||||
| 12/13/2024 | Genmab U.S., Inc. | Epkinly (Drug) | Food and Beverage | In-kind items and services | $23.27 | General |
| Category: Oncology | ||||||
| 12/13/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $20.50 | General |
| 12/13/2024 | Bayer Healthcare Pharmaceuticals Inc. | Nubeqa (Drug), Xofigo | Food and Beverage | In-kind items and services | $20.45 | General |
| Category: Oncology | ||||||
| 12/09/2024 | PFIZER INC. | PADCEV (Biological) | Food and Beverage | In-kind items and services | $20.27 | General |
| Category: Oncology | ||||||
| 12/09/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $19.19 | General |
| Category: ONCOLOGY | ||||||
| 12/06/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $30.21 | General |
| 12/04/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $25.40 | General |
| Category: Oncology | ||||||
| 12/03/2024 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Food and Beverage | In-kind items and services | $20.64 | General |
| Category: Oncology | ||||||
| 12/02/2024 | Astellas Pharma US Inc | Padcev (Drug) | Food and Beverage | In-kind items and services | $24.40 | General |
| Category: Oncology | ||||||
| 11/27/2024 | Novartis Pharmaceuticals Corporation | MEKINIST (Drug) | Food and Beverage | In-kind items and services | $26.66 | General |
| Category: Oncology | ||||||
| 11/25/2024 | Takeda Pharmaceuticals U.S.A., Inc. | FRUZAQLA (Drug) | Food and Beverage | In-kind items and services | $36.45 | General |
| Category: ONCOLOGY | ||||||
| 11/22/2024 | Incyte Corporation | MONJUVI (Drug), PEMAZYRE | Food and Beverage | Cash or cash equivalent | $24.86 | General |
| Category: Oncology | ||||||
| 11/19/2024 | Karyopharm Therapeutics Inc. | XPOVIO (Drug) | Food and Beverage | In-kind items and services | $31.16 | General |
| Category: Oncology | ||||||
| 11/19/2024 | Genentech USA, Inc. | Itovebi (Biological), Phesgo | Food and Beverage | In-kind items and services | $14.58 | General |
| Category: BioOncology | ||||||
| 11/14/2024 | SERVIER PHARMACEUTICALS LLC | Voranigo (Drug) | Food and Beverage | In-kind items and services | $20.99 | General |
| Category: Oncology | ||||||
| 11/13/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $31.62 | General |
| 11/13/2024 | PFIZER INC. | ELREXFIO (Drug), ADCETRIS | Food and Beverage | In-kind items and services | $18.21 | General |
| Category: ONCOLOGY | ||||||
| 11/12/2024 | Ipsen Biopharmaceuticals, Inc | Onivyde (Drug) | Food and Beverage | In-kind items and services | $34.55 | General |
| Category: Oncology | ||||||
| 11/12/2024 | Daiichi Sankyo Inc. | INJECTAFER (Drug) | Food and Beverage | In-kind items and services | $28.77 | General |
| Category: Iron Deficiency Anemia | ||||||
| 11/11/2024 | Genmab U.S., Inc. | Tivdak (Drug) | Food and Beverage | In-kind items and services | $24.07 | General |
| Category: Oncology | ||||||
| 11/11/2024 | Astellas Pharma US Inc | Vyloy (Drug) | Food and Beverage | In-kind items and services | $23.14 | General |
| Category: Oncology | ||||||
| 11/08/2024 | Astellas Pharma US Inc | Vyloy (Drug) | Food and Beverage | In-kind items and services | $26.36 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 36 | 1,426 | 185,876 | $5.6M | $2.0M |
| 2022 | 40 | 1,617 | 179,676 | $4.7M | $2.0M |
| 2021 | 38 | 1,471 | 128,724 | $3.1M | $1.2M |
| 2020 | 36 | 1,548 | 142,237 | $4.1M | $1.9M |
Total Patients
6,062
Total Services
636,513
Medicare Billing
$7.1M
Procedure Codes
150
All Medicare Procedures & Services
150 procedure records from CMS Medicare Utilization — Page 1 of 6
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 14 | 18,600 | $1.7M | $804,936 | 48.5% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 29 | 15,360 | $614,400 | $281,275 | 45.8% |
| J9264 | Injection, paclitaxel protein-bound particles, 1 mg | Office | 2023 | 14 | 23,371 | $584,275 | $234,462 | 40.1% |
| Q5122 | Injection, pegfilgrastim-apgf (nyvepria), biosimilar, 0.5 mg | Office | 2023 | 37 | 2,544 | $941,280 | $226,655 | 24.1% |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 2023 | 45 | 61,200 | $612,000 | $143,390 | 23.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 305 | 889 | $195,550 | $88,411 | 45.2% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 62 | 665 | $214,180 | $72,243 | 33.7% |
| J1439 | Injection, ferric carboxymaltose, 1 mg | Office | 2023 | 20 | 35,250 | $88,125 | $30,781 | 34.9% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 68 | 2,055 | $112,987 | $26,253 | 23.2% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 32 | 169 | $27,040 | $9,185 | 34.0% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 92 | 706 | $35,300 | $8,010 | 22.7% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 14 | 98 | $18,130 | $5,961 | 32.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 37 | 41 | $10,950 | $5,813 | 53.1% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 91 | 828 | $4,140 | $4,057 | 98.0% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 30 | 77 | $13,090 | $4,056 | 31.0% |
| 99195 | Drawing of blood for a medical problem | Office | 2023 | 11 | 49 | $8,440 | $3,699 | 43.8% |
| J2469 | Injection, palonosetron hcl, 25 mcg | Office | 2023 | 47 | 3,833 | $191,650 | $3,542 | 1.8% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 35 | 135 | $10,125 | $3,244 | 32.0% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 22 | 23 | $7,135 | $3,182 | 44.6% |
| 96360 | Infusion into a vein for hydration, 31-60 minutes | Office | 2023 | 28 | 114 | $14,250 | $3,118 | 21.9% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 18 | 44 | $8,610 | $2,855 | 33.2% |
| M0010 | Enhancing oncology model (eom) monthly enhanced oncology services (meos) payment for eom enhanced services | Office | 2023 | 11 | 40 | $2,800 | $2,744 | 98.0% |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | Office | 2023 | 53 | 464 | $11,600 | $1,993 | 17.2% |
| J1453 | Injection, fosaprepitant, 1 mg | Office | 2023 | 30 | 15,450 | $77,250 | $1,761 | 2.3% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 14 | 68 | $4,940 | $1,610 | 32.6% |
About Dr. John Devlin, M.D
Dr. John Devlin, M.D is a Hematology & Oncology healthcare provider based in Bryn Mawr, Pennsylvania. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/14/2007. The National Provider Identifier (NPI) number assigned to this provider is 1073728663.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. John Devlin, M.D has received a total of $29,172 in payments from pharmaceutical and medical device companies, with $4,991 received in 2024. These payments were reported across 1,586 transactions from 99 companies. The most common payment nature is "Food and Beverage" ($27,846).
As a Medicare-enrolled provider, Devlin has provided services to 6,062 Medicare beneficiaries, totaling 636,513 services with total Medicare billing of $7.1M. Data is available for 4 years (2020–2023), covering 150 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Bryn Mawr, PA
- Active Since 05/14/2007
- Last Updated 08/13/2025
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1073728663
Products in Payments
- KEYTRUDA (Biological) $1,410
- OPDIVO (Biological) $1,366
- IMBRUVICA (Drug) $843.67
- XARELTO (Drug) $771.12
- Lenvima (Drug) $694.35
- JAKAFI (Drug) $663.30
- INJECTAFER (Drug) $614.30
- CALQUENCE (Drug) $535.75
- CYRAMZA (Drug) $511.90
- Imbruvica (Drug) $490.52
- TAGRISSO (Drug) $482.93
- ADCETRIS (Biological) $469.83
- ELIQUIS (Drug) $416.36
- IBRANCE (Drug) $378.62
- LYNPARZA (Drug) $370.53
- VERZENIO (Drug) $352.26
- Avastin (Biological) $344.83
- Enhertu (Drug) $311.63
- ENHERTU (Biological) $310.70
- NINLARO (Drug) $306.84
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Bryn Mawr
Dr. Sameer Gupta, Md, Mph, MD, MPH
Hematology & Oncology — Payments: $348,378
Hematology & Oncology $348,378
Eric Fox
Hematology & Oncology — Payments: $11,916
Hematology & Oncology $11,916
Dr. Sandra Schnall, M.d, M.D
Hematology & Oncology — Payments: $10,386
Hematology & Oncology $10,386
Dr. John Garofalo, Md, MD
Hematology & Oncology — Payments: $15.05
Hematology & Oncology $15.05